|
|
||||||||
1 Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität, D-48149 Münster, Germany; and 2 Department of Laboratories, Denver Health Medical Center, Denver, Colorado 80204
| |
ABSTRACT |
|---|
|
|
|---|
Compared with isolated electrically driven
neonatal ventricular preparations, the total time of contraction, the
time to peak tension, and the time of relaxation were decreased to
~50% in adult ventricular preparations. The expression of
sarco(endo)plasmic reticulum
Ca2+-ATPase (SERCA) was increased
to 133% at the protein level and to 154% at the mRNA level in adult
vs. neonatal ventricular preparations, whereas phospholamban was
unchanged at both the protein and mRNA levels. Moreover,
Ca2+ uptake was increased to 180%
in adult vs. neonatal ventricular preparations. Phospholamban
phosphorylation was enhanced in adult vs. neonatal ventricular
preparations. In adult ventricular preparations, phosphatase activity
was reduced to 53% of neonatal preparations, the protein levels of the
immunologically detectable catalytic subunits of protein phosphatase
types 1 and 2A were reduced to 28 and 61% of neonatal preparations,
respectively, and the mRNA levels of type 1
, 1
, 1
, 2A
, and
2A
phosphatase isoforms were decreased to 69, 68, 54, 67, and 63%,
respectively. We conclude that in the adult rat heart, the shortened
time parameters of contraction can be explained by an elevated
expression of SERCA. In addition, an increased phosphorylation state of
phospholamban due to reduced phosphatase activity may be involved.
phospholamban; sarco(endo)plasmic reticulum calcium-adenosinetriphosphatase; calsequestrin; contractility
| |
INTRODUCTION |
|---|
|
|
|---|
MYOCARDIAL CONTRACTILITY changes during the postnatal
development of the mammalian heart (4, 5, 9, 36, 46). A crucial step in
the regulation of myocardial contractility is the dynamic alteration of
intracellular Ca2+ levels by the
sarcoplasmic reticulum (SR). Systolic contraction is brought about by
an increase in free cytosolic
Ca2+, whereas relaxation in
diastole results from active removal of Ca2+ mainly into the SR by the
cardiac sarco(endo)plasmic reticulum Ca2+-ATPase 2a (SERCA, Ref. 31).
It can be hypothesized that altered contractility is associated with a
change of Ca2+ homeostasis of the
SR. Accordingly, a number of studies dealing with the developmental
regulation of SERCA have shown that SERCA expression at mRNA and
protein levels increases after birth (3, 12, 14, 33). Fittingly, the
Ca2+ uptake of the SR is higher in
adult than in fetal or neonatal mammalian hearts (sheep, Refs. 33, 47;
mice, Ref. 14; rat, Ref. 55; rabbit, Refs. 40, 54). However, in
principle, Ca2+ uptake cannot only
be increased by elevation of SERCA protein levels but also by enhancing
SERCA affinity for Ca2+, which is
regulated by the phosphorylation state of phospholamban, a small
intrinsic protein of the SR (for review, see Ref. 21). Only
dephosphorylated phospholamban inhibits SERCA, whereas phosphorylation of phospholamban relieves this inhibition (52, 59). The
-adrenoceptor agonist isoproterenol increased the phosphorylation
state of phospholamban in isolated intact ventricles and increased
SERCA activity (24). Moreover, isoproterenol led to phosphorylation of
phospholamban on serine-16 and threonine-17 by cAMP-dependent and
Ca2+/calmodulin-dependent protein
kinases, respectively (56). Ablation of phospholamban by injection of a
specific antibody (2D12) or by gene targeting mimics the effect of
isoproterenol and stimulates Ca2+
uptake into the SR (29, 52). These data argue that phospholamban is a
prime regulator of basal myocardial contractility and is an important
mediator of the
-adrenergic effects in the heart. However, little is
known about the expression of phospholamban in neonatal vs. adult rat
ventricular preparations. In mouse hearts, phospholamban expression
increased after birth at the protein and mRNA levels (14). In rabbit
hearts, after birth the phospholamban expression did not change on the
mRNA level (3) but increased on the protein level (54). Although a
posttranslational regulation of phospholamban expression has been
suggested (54), the reason for this discrepancy is unknown. Moreover,
it is conceivable that not only the expression but also the
phosphorylation state of phospholamban might be subject to regulation.
Some recent data support the hypothesis that protein phosphatases play
an important role in the regulation of the phosphorylation state of
phospholamban. We have demonstrated that phospholamban phosphorylation
can be stimulated by cell membrane-permeant inhibitors of
serine/threonine phosphatases (for short, phosphatases) type 1 and 2A
such as okadaic acid and cantharidin (42, 44). Like
-adrenoceptor
agonists, these inhibitors can exert a positive inotropic, positive
lusitropic, and positive clinotropic effect (44). On the other hand,
activators of phosphatases can dephosphorylate phospholamban and exert
a negative inotropic effect (59). Type 1 and 2A phosphatases are the
main phosphatases of the myocardium (53, 57). Both phosphatases can
dephosphorylate phospholamban (30), and their activity is reduced by
inhibitors like cantharidin (16). The catalytic subunits are encoded by
separate genes and comprise at least type 1
, 1
, 1
, 2A
, and
2A
isoforms (for review, see Ref. 39). Biochemical data on their
developmental regulation in the heart are currently lacking, however.
We hypothesized that postnatal alterations of cardiac phosphatases might occur and alter the function of SR proteins, and this could result in postnatal changes in contractility, such as shortened duration of contraction. To test this hypothesis, we have measured cardiac time parameters, SR protein expression, and phosphatase expression in neonatal vs. adult mammalian cardiac ventricular preparations.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals.
Sprague-Dawley CD rats from Harlan Winkelmann (Borchen, Germany) were
used for the present studies. Neonatal rats (within 24 h of birth) and
adult rats (220-260 days old) were studied. Rats were killed by a
blow to the head, hearts were rapidly removed, atria were discarded,
and ventricles were immediately used for contractile studies or freeze
clamped with precooled Wollenberger clamps at the temperature of liquid
nitrogen and stored at
80°C. This procedure preserves the
phosphorylation state of proteins (24, 25, 44). The protocols used in
this study were approved by the local animal welfare review board.
Contraction experiments.
Ventricular preparations (ventricular strips, ~8 mm length, <0.6 mm
diameter) were used. The isolated preparations were mounted and bathed
individually in glass tissue chambers for recording isometric
contractions (42). The bathing solution contained (in mM) 119.8 NaCl,
5.4 KCl, 1.8 CaCl2, 1.05 MgCl2, 0.42 NaH2PO4, 22.6 NaHCO3, 0.05 Na2EDTA, 0.28 ascorbic acid, and
5.0 glucose, continuously gassed with 95%
O2-5%
CO2, and was maintained at 35°C and pH 7.4. Isometric force of contraction was measured after each preparation was stretched to optimal length. All preparations were
initially stimulated at 1 Hz with rectangular pulses of 5-ms duration
(Grass stimulator SDS; Grass, Quincy, MA); the voltage was
~10-20% above threshold. Preparations were allowed to
equilibrate for 30 min. In some experiments, the frequency was altered
and stepwise increased from 0.2 to 1.4 Hz. Time from 10% contraction to peak contraction (TPT) and time from peak to 90% relaxation (TR)
were calculated from recordings at high chart speed. Total contraction
time (TCT) is the sum of TPT and TR (42, 44). Isoproterenol
(10
9 to
10
5 M) was then added
cumulatively, allowing 10 min for each concentration.
Ca2+ uptake. Frozen ventricles were homogenized in 250 mM sucrose, 10 µM cantharidin, and 30 mM histidine (pH 7.0). Ca2+ uptake in homogenates was measured by the microfiltration technique with 45Ca2+ (ICN Biomedicals, Eschwege, Germany) (35). The reaction buffer contained 50 mM MOPS (pH 7.0), 3 mM MgCl2, 100 mM KCl, 5 mM NaN3, 10 mM potassium oxalate, 0.5 mM EGTA, 10 µM cantharidin, and different CaCl2 concentrations to give pCa values of 7.49 in accordance with previous work (55). Free Ca2+ concentrations were calculated (6). The effect of the anti-phospholamban monoclonal antibody 2D12 on Ca2+ uptake was measured by preincubation of homogenates with antibody for 20 min on ice. Ca2+ uptake was initiated by addition of 3 mM ATP and then performed at 37°C. Aliquots of 100 µl were filtered at various time points on 0.22-µm filters (GS type, Millipore, Bedford, MA) and washed twice with 5 ml of 150 mM NaCl. The amount of radioactivity on filters was measured by scintillation counting. Initial experiments indicated that incubation for 5 min was in the linear range, and this incubation time was used subsequently.
Analysis of mRNA and Northern blotting. To extract total RNA from the frozen neonatal and adult rat ventricles, a modification of the method described by Chomczynski and Sacchi (10) was employed. Rat ventricles were homogenized using a microdismembrator (B. Braun Melsungen, Melsungen, Germany) in 1 ml TriStar reagent (AGS, Heidelberg, Germany) containing guanidinium thiocyanate and phenol. This homogenate was divided into two parts: one aliquot was used for quantification of protein by SDS-PAGE and Western blotting, and from the other, major, portion, total RNA was extracted in the following way. To 800 µl homogenate, 200 µl chloroform were added, and the resulting two phases were separated by centrifugation. The RNA present in the upper, aqueous, phase was precipitated with the same volume isopropanol and washed twice with 75% ethanol. The RNA pellet was dried under vacuum and then dissolved in diethyl pyrocarbonate-treated water.
Plasmid (pBS) with cDNA inserts for rat SERCA2a (26) and rat phospholamban (38) were a kind gift from Dr. K. R. Boheler (National Institute of Aging, Baltimore, MD). Inserts were isolated by digestion with EcoR I. The cDNA inserts were purified from 1.5% agarose gels. Sizes were ~2,400 bp for SERCA and 1,100 bp for phospholamban. The other cDNA probes were constructed by RT-PCR. First-strand cDNA was reverse transcribed from 1 µg of total rat ventricle tRNA in 10 µl of 50 mM Tris · HCl (pH 8.3), 40 mM KCl, 6.0 mM MgCl2, 1.0 mM each dNTP (Pharmacia, Uppsala, Sweden), 5.0 mM DL-dithiothreitol, 50 µg/ml BSA, 10 units of human placental RNase inhibitor (AGS), and 30 units of TrueScript TM reverse transcriptase (AGS) at 41°C for 60 min. Primers based on the published cDNA sequences for rat protein phosphatase (PP) 1
(51), rat PP1
(51), rat PP1
(51), rat
PP2A
(19), and rat PP2A
(48), for rat calsequestrin (Genbank
accession no. U33287, Aquilla TT and Rovner AS), rat cardiac inhibitory
subunit of troponin (34), and human atrial natriuretic peptide (2) were
employed to generate subtype-specific probes by RT-PCR (Table
1). All PCR reactions were carried out in a
total volume of 50 µl containing 20 mM Tris · HCl
(pH 8.55 at 25°C), 16 mM
(NH4)2SO4,
200 µM each dNTP, 1.5-2.0 mM
MgCl2, and 1.5 units Taq DNA
polymerase (AGS). Each reaction was subjected to 30 cycles of
denaturation (1 min at 94°C), annealing (2 min), and extension (2 min at 72°C). All PCR reactions were performed in a thermal cycler
(Omnigene, model TR3 CM220, MWG-Biotech, Ebersberg, Germany). Sizes of
PCR products were compared with DNA size markers (MBI Fermentas,
Vilnius, Latvia). MgCl2 titration
curves were performed with each pair of primers to optimize
amplification specificity. Single bands of the expected size were
obtained. PCR products were visualized on 2% agarose gels, cut out,
purified by dialysis (50), and used as probes in Northern blots. The
PP2A
PCR product was cut by restriction digest using the enzyme
Dde I, and the 305-bp fragment was
used as a probe. To confirm the identity of PCR products, cycle
sequencing using AmpliTaq-FS DNA polymerase (Applied Biosystems,
Weiterstadt, Germany) and an ABI PRISM-310 automated sequencer (Applied
Biosystems) was performed.
|
-32P]dCTP (New
England Nuclear-Du Pont, Bad Homburg, Germany) by random priming
(Megaprime kit, Amersham Buchler). Hybridized membranes were washed at
a stringency of 0.2× SSC, 0.1% SDS at 60°C and exposed to
PhosphorImager screens, visualized in a PhosphorImager, and quantified
by the ImageQuant software version 3.3 PhosphorImager units
(Molecular Dynamics, Krefeld, Germany). To normalize the amount of RNA
bound to membranes, all blots were also hybridized with 18S ribosomal
RNA as described (23).
Quantitative immunoblotting for phospholamban, SERCA,
calsequestrin, the inhibitory subunit of troponin, and
-actin.
Frozen cardiac ventricles from neonatal and adult rats were homogenized
using a microdismembrator (B. Braun Melsungen) in TriStar reagent
(AGS). An aliquot of 200 µl was assayed for protein, according to the
method of Bradford (8) after TCA precipitation. Samples of cardiac
homogenate were solubilized for electrophoresis by addition of an equal
volume of SDS buffer. Forty micrograms of homogenate sample protein
were loaded per lane. These amounts were in the linear range for each
protein (data not shown). Gels were run using 10% acrylamide
separating gels. After gel electrophoresis, separated proteins were
electrophoretically transferred to nitrocellulose membranes (Schleicher
& Schuell, Dassel, Germany) as described (44). Nitrocellulose sheets
were incubated with antibody A1 raised against phospholamban (BIOMOL,
Hamburg, Germany), antibody 2A7-A1 to SERCA, an affinity-purified
antibody to calsequestrin (32), antibody 2F6.6.51 to the inhibitory
subunit of troponin, and antibody to
-actin (Sigma, Deisenhofen,
Germany). These antibodies have been characterized before (23, 30, 44,
52). Proteins binding antibodies were visualized using
125I-labeled anti-mouse IgG (ICN
Biomedicals) for phospholamban, 125I-protein A (ICN Biomedicals)
for SERCA, the inhibitory subunit of troponin, calsequestrin, and
125I-labeled anti-mouse IgM (ICN
Biomedicals) for
-actin. Radioactive bands were visualized in a
PhosphorImager as described above.
Quantitative immunoblotting for PP1 and PP2A.
Frozen cardiac ventricles from neonatal and adult rats were homogenized
in buffer containing 20 mM Tris, 5 mM
MgCl2, 1 mM EDTA, 1 mM
dithiothreitol, 0.4 mM phenylmethylsulfonyl fluoride, and 1 g/l
leupeptin. SDS gel electrophoresis was performed on 10% polyacrylamide
gels (27). Immunoblot analysis was performed after electrophoretic
transfer of proteins to nitrocellulose membranes that were then
incubated for 8 h with a buffer (10 mM Tris, 154 mM NaCl; TBS)
containing 0.1% Tween 20 (TTBS) and 5% nonfat dry milk to block
nonspecific protein binding sites on the nitrocellulose. The antibodies
against the catalytic subunits for PP1
, PP2A
, and PP2A
(catalogue no. 06-221, lot no. 12641 and catalogue no. 06-222, lot no. 13949; BIOMOL) at 2 µg/ml dilution in blocking buffer were incubated with the blot overnight. These antibodies recognized a band at the expected molecular mass of ~36 kDa that was
quantified. After several rinses in TTBS, the nitrocellulose was
incubated with 125I-labeled goat
anti-rabbit IgG (ICN Biomedicals) diluted 1:1,000 in TBS for 4 h at
room temperature. After several washes with TTBS and then once with
TBS, the nitrocellulose membranes were dried and the radioactive bands
were visualized in a PhosphorImager and quantified as described for
Northern blotting. Specificity of immunologic signals was verified by
blocking experiments as described (20).
Immunoblots for mobility shift and phosphorylation.
Frozen cardiac ventricles from neonatal and adult rats were homogenized
at 4°C three times for 30 s each with Polytron PT-10 (Kinematica,
Lucerne, Switzerland) in 300 µl of 10 mM
NaHCO3. Then 100 µl of 20% SDS
were added. SDS inhibits protein kinases and phosphatases and preserves
thus the phosphorylation state of proteins (42). Mixtures were kept at
25°C for 30 min before centrifugation to remove debris. Thereafter,
supernatants (called extracts) were kept at
20°C until
further analysis. Protein concentrations were determined by the Lowry
assay (27). SDS extracts were thawed, and additional SDS buffer (22)
was added. Samples were incubated for 10 min at 30°C. Forty
micrograms of homogenate sample protein were loaded per lane. SDS gel
electrophoresis was performed on 10% polyacrylamide gels, and proteins
were electroblotted to nitrocellulose membranes (Schleicher & Schuell)
as described (43). This modified Laemmli system is able to separate the
low- and high-molecular-weight forms of phospholamban (e.g., Refs. 24,
44). Nitrocellulose sheets were incubated with the monoclonal antibody
A1 raised against phospholamban (BIOMOL). Under our assay conditions,
the affinity of the antibody did not depend on the phosphorylation
state of phospholamban (see also Ref. 11 and Fig.
7B). Proteins binding antibodies
were visualized using 125I-labeled
anti-mouse IgG (ICN Biomedicals). Radioactive bands were visualized by
a PhosphorImager as described for Northern blotting.
Preparation of membrane vesicles.
Membrane vesicles were prepared as described previously (1) with minor
modifications. Frozen neonatal rat ventricles were homogenized in 10 ml
of medium containing (in mM) 4.0 EDTA, 1.0 Na4H2PO7,
and 0.1% (vol/vol)
-mercaptoethanol. The tissue was homogenized
three times for 30 s each with a Polytron PT-10 (Kinematica). The
sample was sedimented for 20 min at 14,000 g. The supernatant was sedimented at
45,000 g for 30 min, and the resulting
pellet was resuspended in 10 ml of homogenization medium containing 0.6 M NaCl. This material was sedimented at 45,000 g for 30 min. The final pellet
containing the membrane vesicles was resuspended in 200 µl of 50 mM
Tris · HCl (pH 7.0), 0.1 mM EDTA, and 0.1%
-mercaptoethanol. The membrane vesicles (10 µg protein/assay) were
immediately phosphorylated in a medium (final volume 50 µl) containing (in mM) 40 histidine HCl (pH 6.8), 10 MgCl2, 15 NaF, 1 EGTA, and 0.75 ATP at 37°C. The reaction was initiated by the addition of ATP.
After 2 h, 5 µl of a solution of BSA (10 mg/ml) and 3 ml of 15% TCA
containing 50 mM
H3PO4
and 0.5 mM ATP were added. After centrifugation at 4°C, the
precipitates were processed as described in Ref. 18. The
electrophoretic separation was performed on 10% polyacrylamide gels
according to Laemmli (22). Phospholamban was identified by
immunoblotting as described above.
PP assay.
Assays for PP activity were performed exactly as described previously
(42). Phosphatase activity was measured at 30°C using [32P]phosphorylase as
a substrate. The 50 µl incubation mixture contained (in mM) 20.0 Tris
(pH 7.0), 5.0 caffeine, 0.1 EDTA, and 0.1% (vol/vol)
-mercaptoethanol. The reaction was terminated after 10 min by addition of TCA. Samples were centrifuged, and radioactivity in the
supernatants was determined by scintillation counting.
Statistics. Data shown are means ± SE. Statistical analysis was performed using Student's t-test or by two-way ANOVA followed by Bonferroni's t-test as appropriate. A P value <0.05 was considered significant.
| |
RESULTS |
|---|
|
|
|---|
Contractile response.
TCT, TPT, and TR were about twofold longer in neonatal compared with
adult ventricular preparations [259.0 ± 8.86 vs. 126.1 ± 4.77 ms (TCT), 106.0 ± 4.85 vs. 52.8 ± 2.52 ms (TPT), 153.0 ± 4.90 vs. 73.3 ± 2.50 ms (TR);
n = 5-9, 1 Hz,
P < 0.05]. Similar results
were obtained at lower (0.2 Hz) and higher (1.4 Hz) rates of
stimulation (data not shown). As expected, isoproterenol cumulatively applied (0.001-10 µM) shortened time parameters in adult and
neonatal preparations in a concentration-dependent manner. The effect
was maximal at 10 µM isoproterenol (data not shown). In neonatal rat ventricular preparations, 10 µM isoproterenol shortened TPT by 39%
(from 106 ± 4.85 to 64 ± 1.7 ms,
n = 5-7,
P < 0.05) and TR by 40.7% (from 153 ± 4.90 to 91 ± 10.14 ms, n = 5-7, P < 0.05). In adult
ventricular preparations, 10 µM isoproterenol shortened TPT by 17.9%
(from 53 ± 2.52 to 43 ± 1.44 ms,
n = 9, P < 0.05) and TR by 28.8% (from 73 ± 2.50 to 52 ± 2.37 ms, n = 9, P < 0.05). It is noteworthy that
after maximum
-adrenergic stimulation, the duration of contraction
in neonatal preparations was 21% longer than in adult preparations.
SR Ca2+
uptake.
To determine whether developmental changes in SR function occur,
Ca2+ uptake measurements were
performed. SR Ca2+ uptake in adult
preparations amounted to 0.30 ± 0.09 Ca2+ · mg
protein
1 · min
1, whereas
Ca2+ uptake was 0.06 ± 0.01 Ca2+ · mg
protein
1 · min
1
in neonatal preparations (n = 5, P < 0.05 neonatal vs. adult). Ca2+ uptake was stimulated to 0.83 ± 0.12 and 0.26 ± 0.06 Ca2+ · mg
protein
1 · min
1
in adult and neonatal preparations, respectively, in the presence of
anti-phospholamban antibody 2D12 (n = 5, P < 0.05 neonatal vs. adult).
Quantification of SERCA, phospholamban, calsequestrin, the inhibitory subunit of troponin, and atrial natriuretic peptide mRNA levels. Total RNA was isolated from neonatal and adult rat ventricles. In Northern blots from both adult and neonatal ventricles, the following transcripts were detectable: one transcript of 4.4 kb for SERCA (Fig. 1A), two major transcripts of 1.1 and 3.3 kb for phospholamban (Fig. 1B), one transcript of 2.9 kb for calsequestrin (Fig. 1C), one transcript of 0.7 kb for the inhibitory subunit of troponin (Fig. 1D), and one transcript of 0.7 kb for the atrial natriuretic peptide (Fig. 1E). Comparing adult and neonatal preparations, we found that the content of Ca2+-ATPase mRNA level was lower in the neonatal rat ventricle than in the adult (0.28 ± 0.02 vs. 0.58 ± 0.03 PhosphorImager units, n = 3, P < 0.05). In contrast, phospholamban mRNA expression level was unchanged (4.86 ± 0.30 vs. 4.64 ± 0.27 PhosphorImager units, n = 3). Calsequestrin mRNA level was lower in the neonatal rat ventricle (1.03 ± 0.09 vs. 2.30 ± 0.14 PhosphorImager units, n = 3, P < 0.05); the mRNA for the inhibitory subunit of troponin was likewise less abundant in neonatal compared with adult ventricles (1.89 ± 0.36 vs. 3.49 ± 0.11 PhosphorImager units, n = 3, P < 0.05). In contrast, atrial natriuretic peptide mRNA level was markedly higher in neonatal than in adult ventricular preparations (6.80 ± 0.40 vs. 1.05 ± 0.07 PhosphorImager units, n = 3, P < 0.05).
|
Quantification of SERCA, phospholamban, calsequestrin, the
inhibitory subunit of troponin, and
-actin protein
levels.
mRNA levels have often been used to predict changes at the protein
level. However, there is evidence that protein and mRNA levels, for
instance, of phospholamban or SERCA, do not always correlate (23, 37).
Thus it was important to determine whether the observed changes at mRNA
levels in the developing hearts reflected changes at protein levels.
Quantitative immunoblotting was used to determine the expression of
SERCA, phospholamban, calsequestrin, the inhibitory subunit of
troponin, and
-actin. Initial experiments showed that the detection
method was linear between 20 and 60 µg protein of ventricular
homogenate (e.g., for the inhibitory subunit of troponin, Fig.
2). Thus 40 µg protein were used for quantitative immunoblotting. SERCA protein expression in adult ventricular preparations was 3.3-fold of values in neonatal
preparations (27.4 ± 0.82 vs. 8.36 ± 1.23 PhosphorImager
units, n = 5, P < 0.05, Fig.
3). The expression of phospholamban and
-actin was unchanged (8.55 ± 0.41 vs. 8.67 ± 0.32 PhosphorImager units for phospholamban and 1.30 ± 0.17 vs. 1.34 ± 0.16 PhosphorImager units for
-actin,
n = 4 or 5, Figs. 3 and
7A). Protein levels of calsequestrin and the inhibitory subunit of troponin were lower in neonatal ventricular preparations and amounted to 63% (4.03 ± 0.30 vs. 6.35 ± 0.32 PhosphorImager units, n = 5, P < 0.05, Fig. 3) and 23% (8.55 ± 0.73 vs. 36.73 ± 2.91 PhosphorImager units,
n = 5, P < 0.05, Fig. 3) of those in adult
preparations.
|
|
Phosphatase activity.
We compared phosphatase activity in ventricular homogenates from
neonatal and adult rat ventricles. Phosphatase activity was higher in
neonatal rat ventricle preparations compared with adult (1,020 ± 59 nmol · mg
protein
1 · min
1
in neonatal to 540 ± 33 nmol · mg
protein
1 · min
1
in adult, n = 9 or 10, P < 0.05).
Phosphatase expression at mRNA and protein levels.
To understand the underlying mechanism of enhanced phosphatase
activity, the mRNA and protein expression of the catalytic subunits of
PP1 and PP2A were studied in neonatal and adult rat ventricular
preparations. In neonatal and adult ventricular preparations, Northern
blots showed transcripts for PP1
at 1.8 kb (Fig.
4A); for
PP1
at 3.2 kb (Fig. 4B); for
PP1
at 1.6 and 2.6 kb (Fig. 4C);
for PP2A
at 1.1, 2.0, and 2.7 kb (Fig.
5A); and
for PP2A
at 2.0 kb (Fig. 5B).
Summarizing the data of all experiments, we found that the mRNA in
neonatal preparations for PP1
amounted to 145%, PP1
amounted to
148%, PP1
amounted to 185%, PP2A
amounted to 150%, and PP2A
amounted to 158% of adult ventricular mRNA (Figs.
4D and
5C). Data of protein expression
correlated with mRNA expression. Quantitative immunoblotting with the
antibodies for PP1
and for PP2A was performed. Protein levels of PP1
in neonatal ventricular preparations were elevated to 354%, and
protein expression of PP2A amounted to 165% of adult ventricular
values (Fig. 6,
A and
B).
|
|
|
Mobility shift and phosphorylation of phospholamban. Phosphorylation of phospholamban leads to a higher apparent molecular mass of pentameric phospholamban in SDS-PAGE as described before (56). Interestingly, we observed that the apparent molecular mass of phospholamban was higher in adult rat ventricles than in neonatal ventricles (Fig. 7A), suggesting a higher state of phosphorylation of phospholamban in adult cardiac preparations. This interpretation is supported by the fact that phosphorylation of phospholamban from neonatal ventricular preparations by exogenous cAMP-dependent protein kinase decreased the mobility of phospholamban under the same conditions (Fig. 7B).
|
| |
DISCUSSION |
|---|
|
|
|---|
There are conflicting reports whether duration of contraction declines or increases after birth. The time parameters are longer in adult feline and canine hearts than in neonatal hearts (36, 46). The underlying biochemical reason for this change is speculative; postnatal developmental regulations of, for example, phospholamban and SERCA expression in feline or canine hearts have not yet been reported. In mouse heart, the expression of both phospholamban and SERCA increased in parallel during maturation (14). However, contractile measurements are apparently lacking in neonatal vs. adult mouse ventricular preparations. Time parameters of contraction were shortened in ventricular preparations from adult vs. neonatal rabbits (4). In rabbit, mRNA data indicated that phospholamban is unchanged and SERCA is increased on maturation but protein data are apparently lacking (3). In rats, reduced developed tension, prolonged TPT, and prolonged TR have been observed in neonatal vs. adult ventricular preparations (9). These contractile measurements in rats are in agreement with our present findings. The purpose of the present work was to further our understanding on the biochemical basis for these contractile differences between adult and neonatal hearts using an integrative approach in one animal species (rat).
We detected an enhanced expression (on mRNA and protein levels) of the
cardiac form of the inhibitory subunit of troponin in adult rat
ventricular preparations compared with neonatal ventricular preparations in accordance with previous work in the rat heart (49,
34). Our results indicate an increase in the inhibitory subunit of
troponin in relation to
-actin.
-Adrenergic stimulation phosphorylates the inhibitory subunit of troponin in isolated cardiac
preparations, and this phosphorylation is thought to contribute to the
relaxant effect of
-adrenergic stimulation. Thus an enhanced level
of unphosphorylated inhibitory subunit of troponin in adult ventricles
is expected to lead to prolonged relaxation. Paradoxically, shortened
relaxation is actually observed in adult preparations. It could be
speculated that the effect of enhanced levels of the inhibitory subunit
of troponin might be functionally antagonized, at least in part, by an
enhanced phosphorylation state of the inhibitory subunit of troponin in
adult preparations due to reduced activity of protein phosphatases (see
below).
The main Ca2+ binding protein of the heart is situated in the junctional and corbular SR and has been termed calsequestrin (32). Increased calsequestrin levels in adult vs. fetal hearts have been observed in rabbit (3) and sheep (33). Postnatal increases have been noted in rabbit heart (3). Data for calsequestrin in rat cardiac development have previously not been available. In the present study, we noted a higher expression of calsequestrin in adult vs. neonatal rat ventricular preparations at mRNA and protein levels.
Unphosphorylated phospholamban reduces the ability of SERCA to pump Ca2+ from the cytosol into the SR (21). This inhibition can be relieved by phosphorylation by cAMP-dependent protein kinase.
cAMP-elevating agents, like the
-adrenoceptor agonist isoproterenol,
increase phospholamban phosphorylation in the heart and enhance
Ca2+ uptake (13, 24). Moreover,
the Ca2+ uptake of the cardiac SR
can be stimulated by incubation with an anti-phospholamban antibody
(2D12) that impedes the interaction of phospholamban with SERCA (52).
Conflicting data have been reported on the postnatal regulation of phospholamban expression. After birth, a parallel increase in phospholamban expression on protein and mRNA levels was noted in mouse heart (14). In sheep, an increase in phospholamban protein level was noted in adult vs. fetal hearts (33). In rabbits, no change in phospholamban mRNA was detectable in fetal, neonatal, or adult hearts (3). Thus it appears that species differences in postnatal phospholamban expression exist and rat cardiac differences have not been studied before. Here, we report that phospholamban levels are unchanged during rat cardiac development on both protein and mRNA levels.
There is general agreement in the literature that SERCA expression is increased during development. For example, there is an increase in SERCA at the protein level in fetal, neonatal, and adult sheep hearts (47). SERCA mRNA increased gradually from fetal to neonatal and to adult rabbit hearts (3). Recently, a postnatal increase in SERCA on protein and mRNA level was reported in the mouse heart (14), whereas data in rat heart are apparently lacking. The new information here is that SERCA was increased (on mRNA and protein level) postnatally. This increase was accompanied by an increased Ca2+ uptake. An increase in Ca2+ uptake has been noted before in sheep heart (47), mouse heart (14), or rat heart (41, 55). We extend on previous work by showing that ablation of phospholamban inhibition of SERCA function by use of the anti-phospholamban antibody 2D12 could stimulate Ca2+ uptake in both neonatal and adult preparations. This antibody offers the possibility to assess the maximal SERCA-mediated Ca2+ uptake. This maximum Ca2+ uptake was greatly increased postnatally. This is expected if phospholamban is functionally active in both neonatal and adult ventricular preparations. Finally, the higher maximum Ca2+ uptake data are consistent with elevated SERCA protein levels in adult in comparison with neonatal rat ventricular preparations.
It can be asked whether the change in SERCA and calsequestrin relative to phospholamban expression is mainly because of histological changes of the SR after birth. Anatomic changes in the SR are well known. For instance, the t-tubule system develops only after birth (15, 45). It can be suggested that the relative amount of the SR in the cells increases, and this could account for all biochemical alterations that were observed in the present study. However, SERCA is mainly detectable in the free SR, whereas calsequestrin is present in the corbular and junctional SR (17). Hence, the present data at least indicate that the amounts of two proteins (SERCA and calsequestrin) located in different parts of the SR increase postnatally related to phospholamban (mainly located in the free SR). A caveat is in order that an optimal constant denominator for postnatal changes in SR proteins is not readily available. Even muscle lipids change postnatally (7).
One should bear in mind that altered expression of other proteins that affect the Ca2+ homeostasis in the heart might also affect duration of contraction. For instance, there is evidence that the expression of the ryanodine receptor (Ca2+-release channel, feet, pedes) or the L-type calcium channel is changed postnatally in the heart (58). For instance, the current through L-type Ca2+ channels and the channel density (by radioligand binding) is increased postnatally (58, 28). Interestingly, currents through L-type Ca2+ currents were differently increased by phosphatase inhibitors in adult vs. neonatal rabbit cardiac cells. Hence, the authors (28) suggested that the phosphatase activity (mainly type 1) might decline postnatally. However, no biochemical measurements of phosphatases or their activity were performed.
Type 1 and 2A phosphatases comprise >90% of phosphatase activity in
the heart and dephosphorylate, for instance, phospholamban (53). We
were able to detect the catalytic subunits of 1
, 1
, 1
, 2A
,
and 2A
in the neonatal and adult rat hearts by Northern blotting.
Interestingly, the mRNA and the protein expression of phosphatase type
1 and type 2A declined postnatally. Fittingly, phosphatase activity was
diminished in preparations from adult vs. neonatal hearts. The
phosphatase activity was composed of type 1 and type 2A phosphatases
under our assay conditions. Both phosphatases can dephosphorylate
phospholamban. Therefore, we expected that phospholamban from neonatal
and adult ventricular preparations should exhibit a different
phosphorylation state. Dephosphorylated pentameric phospholamban
migrates faster on gels than phosphorylated phospholamban (56). Hence,
the slower migration of phospholamban isolated from adult
compared with phospholamban from neonatal ventricular
preparations indicates enhanced phosphorylation of phospholamban in
adult preparations. We suggest that this may in part result from
reduced phosphatase activity in adult compared with neonatal
ventricles.
In summary, SERCA but not phospholamban expression changed postnatally, and this increase is accompanied by enhanced Ca2+ uptake. The repressor function of phospholamban on SERCA is diminished in adult myocardium by a reduced phosphorylation state of phospholamban. This could result from the observed decreased activity and expression of type 1 and 2A phosphatase isoforms in adult hearts. This is the first biochemical report on developmental regulation of phosphatases in the heart.
| |
ACKNOWLEDGEMENTS |
|---|
The excellent technical assistance of R. Plitzko is gratefully acknowledged. We thank Dr. K. R. Boheler for kindly providing the rat SERCA2a cDNA and rat phospholamban cDNA. We thank Dr. L. R Jones (Indianapolis, IN) for supplying antibodies against SERCA and calsequestrin.
| |
FOOTNOTES |
|---|
This work was supported by the Deutsche Forschungsgemeinschaft, the Konferenz der Deutschen Akademien der Wissenschaften, the Deutsche Herzstiftung, and the Deutsche Gesellschaft für Herz- und Kreislaufforschung.
I. Gombosová was on leave from Katedra Farmakológie a Toxikológie, FaF UK, Kalinciakova 8, SK-83232 Bratislava, Slovak Republic.
Address for reprint requests: I. Gombosová, Institut für
Pharmakologie und Toxikologie, Westfälische
Wilhelms-Universität Münster, Domagkstra
e 12, D-48149
Münster, Germany.
Received 14 July 1997; accepted in final form 3 March 1998.
| |
REFERENCES |
|---|
|
|
|---|
1.
Ahmad, Z.,
F. J. Green,
H. S. Suhubi,
and
A. M. Watanabe.
Autonomic regulation of type 1 protein phosphatase in cardiac muscle.
J. Biol. Chem.
264:
3859-3863,
1989
2.
Arai, M.,
N. R. Alpert,
D. H. MacLennan,
P. Barton,
and
M. Periasamy.
Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium.
Circ. Res.
72:
463-469,
1993
3.
Arai, M.,
K. Otsu,
D. H. MacLennan,
and
M. Periasamy.
Regulation of sarcoplasmic reticulum gene expression during cardiac and skeletal muscle development.
Am. J. Physiol.
262 (Cell Physiol. 31):
C614-C620,
1992
4.
Artman, M.
Developmental changes in myocardial contractile responses to inotropic agents.
Cardiovasc. Res.
26:
3-13,
1992
5.
Artman, M.,
P. A. Kithas,
J. S. Wike,
and
S. J. Strada.
Inotropic responses change during postnatal maturation in rabbit.
Am. J. Physiol.
255 (Heart Circ. Physiol. 24):
H335-H342,
1988
6.
Bers, D.,
C. Patton,
and
R. Nuccitelli.
Methods in Cell Biology: A Practical Guide to the Study of Ca2+ in Living Cells. Orlando, FL: Academic, 1994, vol. 40.
7.
Boland, R.,
T. Chyn,
D. Roufa,
E. Reyes,
and
A. Martonosi.
The lipid composition of muscle cells during development.
Biochim. Biophys. Acta
489:
349-359,
1977[Medline].
8.
Bradford, M. M.
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
Anal. Biochem.
72:
248-254,
1976[Medline].
9.
Chemla, D.,
Y. Lecarpentier,
J. L. Martin,
M. Clergue,
A. Antonetti,
and
Y. Hatt.
Relationship between inotropy and relaxation in rat myocardium.
Am. J. Physiol.
250 (Heart Circ. Physiol. 19):
H1008-H1016,
1986.
10.
Chomczynski, P.,
and
N. Sacchi.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:
156-159,
1987[Medline].
11.
Drago, G. A.,
and
J. Colyer.
Discrimination between two sites of phosphorylation on adjacent amino acids by phosphorylation site-specific antibodies to phospholamban.
J. Biol. Chem.
269:
25073-25077,
1994
12.
Fisher, D. J.,
C. A. Tate,
and
S. Phillips.
Developmental regulation of the sarcoplasmic reticulum calcium pump in the rabbit heart.
Pediatr. Res.
31:
474-479,
1992[Medline].
13.
Gupta, R. C.,
J. Neumann,
P. Durant,
and
A. M. Watanabe.
A1-adenosine receptor-mediated inhibition of isoproterenol-stimulated protein phosphorylation in ventricular myocytes. Evidence against a cAMP-dependent effect.
Circ. Res.
72:
65-74,
1993
14.
Harrer, J. M.,
K. Haghighi,
H. W. Kim,
D. G. Ferguson,
and
E. G. Kranias.
Coordinate regulation of SR Ca2+-ATPase and phospholamban expression in developing murine heart.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H57-H66,
1997
15.
Hopkins, S. F.,
E. P. McCutcheon,
and
D. R. Wekstein.
Postnatal changes in rat ventricular function.
Circ. Res.
32:
685-691,
1973
16.
Hunter, T.
Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling.
Cell
80:
225-236,
1995[Medline].
17.
Jorgensen, A. O.,
R. Broderick,
A. P. Somlyo,
and
A. V. Somlyo.
Two structurally distinct calcium storage sites in rat cardiac sarcoplasmic reticulum: an electron microprobe analysis study.
Circ. Res.
63:
1060-1069,
1988
18.
Karczewski, P.,
S. Bartel,
and
E. G. Krause.
Differential sensitivity to isoproterenol of phospholamban and troponin I phosphorylation in isolated rat hearts.
Biochem. J.
266:
115-122,
1990[Medline].
19.
Kitagawa, Y.,
T. Tahira,
I. Ikeda,
K. Kikuchi,
S. Tsuiki,
T. Sugimura,
and
M. Nagao.
Molecular cloning of cDNA for catalytic subunit of rat liver type 2A protein phosphatase, and detection of high levels of expression of the gene in normal and cancer cells.
Biochim. Biophys. Acta
951:
123-129,
1988[Medline].
20.
Knapp, J.,
P. Boknik,
S. Huke,
H. Lüss,
F. U. Müller,
T. Müller,
P. Nacke,
W. Schmitz,
U. Vahlensieck,
and
J. Neumann.
On the mechanism of action of cantharidin in smooth muscle
Br. J. Pharmacol.
123:
911-919,
1988[Medline].
21.
Koss, K. L.,
and
E. G. Kranias.
Phospholamban: a prominent regulator of myocardial contractility.
Circ. Res.
79:
1059-1063,
1996
22.
Laemmli, U. K.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:
680-685,
1970[Medline].
23.
Linck, B.,
P. Boknik,
T. Eschenhagen,
F. U. Müller,
J. Neumann,
M. Nose,
L. R. Jones,
W. Schmitz,
and
H. Scholz.
Messenger RNA expression and immunological quantification of phospholamban and SR-Ca2+-ATPase in failing and nonfailing human hearts.
Cardiovasc. Res.
31:
625-632,
1996[Medline].
24.
Lindemann, J. P.,
L. R. Jones,
D. R. Hathaway,
B. G. Henry,
and
A. M. Watanabe.
-Adrenergic stimulation of phospholamban phosphorylation and Ca2+-ATPase activity in guinea pig ventricles.
J. Biol. Chem.
258:
464-471,
1983
25.
Lindemann, J. P.,
and
A. M. Watanabe.
Muscarinic cholinergic inhibition of
-adrenergic stimulation of phospholamban phosphorylation and Ca2+ transport in guinea pig ventricles.
J. Biol. Chem.
260:
13122-13129,
1985
26.
Lompre, A. M.,
D. De la Bastie,
K. R. Boheler,
and
K. Schwartz.
Characterization and expression of the rat heart sarcoplasmic reticulum Ca2+-ATPase mRNA.
FEBS Lett.
249:
35-41,
1989[Medline].
27.
Lowry, O. H.,
N. J. Rosebrough,
A. L. Farr,
and
R. J. Randall.
Protein measurement with the Folin phenol reagent.
J. Biol. Chem.
193:
265-275,
1951
28.
Lu, C.,
R. Kumar,
T. Akita,
and
R. W. Joyner.
Developmental changes in the actions of phosphatase inhibitors on calcium current of rabbit heart cells.
Pflügers Arch.
427:
389-398,
1994[Medline].
29.
Luo, W.,
I. L. Grupp,
J. Harrer,
S. Ponniah,
G. Grupp,
J. J. Duffy,
T. Doetschman,
and
E. G. Kranias.
Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of
-agonist stimulation.
Circ. Res.
75:
401-409,
1994
30.
MacDougall, L. K.,
L. R. Jones,
and
P. K. Cohen.
Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospholamban.
Eur. J. Biochem.
196:
725-734,
1991[Medline].
31.
MacLennan, D. H.,
C. J. Brandl,
B. Korczak,
and
N. M. Green.
Amino-acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence.
Nature
316:
696-700,
1985[Medline].
32.
MacLennan, D. H.,
and
T. S. Wong.
Isolation of a calcium sequestering protein from sarcoplasmic reticulum.
Proc. Natl. Acad. Sci. USA
68:
1231-1235,
1971
33.
Mahony, L.,
and
L. R. Jones.
Developmental changes in cardiac sarcoplasmic reticulum in sheep.
J. Biol. Chem.
261:
15257-15265,
1986
34.
Martin, A. F.,
and
J. Orlowski.
Molecular cloning and developmental expression of the rat cardiac-specific isoform of troponin I.
J. Mol. Cell. Cardiol.
23:
583-588,
1991[Medline].
35.
Martonosi, A.,
and
R. Feretos.
Sarcoplasmic reticulum. I. The uptake of Ca2+ by sarcoplasmic reticulum fragments.
J. Biol. Chem.
239:
648-658,
1964
36.
Maylie, J. G.
Excitation-contraction coupling in neonatal and adult myocardium of cat.
Am. J. Physiol.
242 (Heart Circ. Physiol. 11):
H834-H843,
1982.
37.
Mearow, K. M.,
B. G. Thilander,
I. Khan,
R. E. Garfield,
and
A. K. Grover.
In situ hybridization and immunocytochemical localization of SERCA2 encoded Ca2+ pump in rabbit heart and stomach.
Mol. Cell. Biochem.
121:
155-165,
1993[Medline].
38.
Moorman, A. F. M.,
J. L. M. Vermeulen,
M. U. Koban,
K. Schwartz,
W. H. Lamers,
and
K. R. Boheler.
Patterns of expression of sarcoplasmic reticulum Ca2+-ATPase and phospholamban mRNAs during rat heart development.
Circ. Res.
76:
616-625,
1995
39.
Mumby, M. C.,
and
G. Walter.
Protein serine/threonine phosphatases: structure, regulation, and functions in cell growth.
Physiol. Rev.
73:
673-699,
1993
40.
Nakanishi, T.,
and
J. M. Jarmakani.
Developmental changes in myocardial mechanical function and subcellular organelles.
Am. J. Physiol.
246 (Heart Circ. Physiol. 15):
H615-H625,
1984.
41.
Narayanan, N.
Differential alterations in ATP-supported calcium transport activities of sarcoplasmic reticulum and sarcolemma of aging myocardium.
Biochim. Biophys. Acta
678:
442-459,
1981[Medline].
42.
Neumann, J.,
P. Boknik,
S. Herzig,
R. C. Gupta,
A. M. Watanabe,
W. Schmitz,
and
H. Scholz.
Evidence for physiological functions of protein phosphatases in the heart. Evaluation with okadaic acid.
Am. J. Physiol.
265 (Heart Circ. Physiol. 34):
H257-H266,
1993
43.
Neumann, J.,
R. C. Gupta,
W. Schmitz,
H. Scholz,
A. C. Nairn,
and
A. M. Watanabe.
Evidence for isoproterenol-induced phosphorylation of phosphatase inhibitor-1 in the intact heart.
Circ. Res.
69:
1450-1457,
1991
44.
Neumann, J.,
S. Herzig,
P. Boknik,
M. Apel,
G. Kaspareit,
W. Schmitz,
H. Scholz,
and
N. Zimmermann.
On the cardiac contractile, biochemical and electrophysiological effects of cantharidin, a phosphatase inhibitor.
J. Pharmacol. Exp. Ther.
274:
530-539,
1995
45.
Page, E., J. Earley, and B. Power. Normal growth of
ultrastructures in rat left ventricular myocardial cells.
Circ. Res. 34, Suppl. II: II-12-II-16, 1974.
46.
Park, I. S.,
L. H. Michael,
and
D. J. Driscoll.
Comparative response of the developing canine myocardium to inotropic agents.
Am. J. Physiol.
242 (Heart Circ. Physiol. 11):
H13-H18,
1982.
47.
Pegg, W.,
and
M. Michalak.
Differentiation of sarcoplasmic reticulum during cardiac myogenesis.
Am. J. Physiol.
252 (Heart Circ. Physiol. 21):
H22-H31,
1987
48.
Posas, F.,
and
J. Arino.
Nucleotide sequence of a rat heart cDNA encoding the isotype beta of the catalytic subunit of protein phosphatase 2A.
Nucleic Acids Res.
17:
8370,
1989
49.
Saggin, L.,
L. Gorza,
S. Ausoni,
and
S. Schiaffino.
Troponin I switching in the developing heart.
J. Biol. Chem.
264:
16299-16302,
1989
50.
Sambrook, J.,
E. F. Fritsch,
and
T. Maniatis.
Molecular Cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
51.
Sasaki, K.,
H. Shima,
Y. Kitagawa,
S. Irino,
T. Sugimura,
and
M. Nagao.
Identification of members of the protein phosphatase 1 gene family in the rat and enhanced expression of protein phosphatase 1
gene in rat hepatocellular carcinomas.
Jpn. J. Cancer Res.
81:
1272-1280,
1990[Medline].
52.
Sham, S. J. K.,
L. R. Jones,
and
M. Morad.
Phospholamban mediates
-adrenergic enhanced Ca2+ uptake in mammalian ventricular myocytes.
Am. J. Physiol.
261 (Heart Circ. Physiol. 30):
H1344-H1349,
1991
53.
Shenolikar, S.,
and
A. C. Nairn.
Protein phosphatases: recent progress.
In: Advances in Second Messenger and Phosphoprotein Research, edited by P. Greengard,
and G. A. Robinson. New York: Raven, 1991, p. 1-121.
54.
Szymanska, G.,
I. L. Grupp,
J. P. Slack,
J. M. Harrer,
and
E. G. Kranias.
Alterations in sarcoplasmic reticulum calcium uptake, relaxation parameters and their responses to
-adrenergic agonists in the developing rabbit heart.
J. Mol. Cell. Cardiol.
27:
1819-1829,
1995[Medline].
55.
Vetter, R.,
R. Studer,
H. Reinecke,
F. Kolar,
I. Ostadalova,
and
H. Drexler.
Reciprocal changes in post-natal expression of sarcolemmal Na+-Ca2+ exchanger and SERCA2 in rat heart.
J. Mol. Cell. Cardiol.
27:
1689-1670,
1995[Medline].
56.
Wegener, A. D.,
J. P. Lindemann,
H. K. B. Simmerman,
and
L. R. Jones.
Phospholamban phosphorylation in intact ventricles.
J. Biol. Chem.
264:
11468-11474,
1989
57.
Wera, S.,
and
B. A. Hemmings.
Serine/threonine protein phosphatases.
Biochem. J.
311:
17-29,
1995.
58.
Wibo, M.,
G. Bravo,
and
T. Godfraind.
Postnatal maturation of excitation-contraction coupling in rat ventricle in relation to the subcellular localization and surface density of 1,4-dihydropyridine and ryanodine receptors.
Circ. Res.
68:
662-773,
1991
59.
Zimmermann, N.,
P. Boknik,
E. Gams,
S. Gsell,
L. R. Jones,
R. Maas,
J. Neumann,
and
H. Scholz.
Mechanism of the contractile effects of 2,3-butanedione-monoxime in the mammalian heart.
Naunyn Schmiedebergs Arch. Pharmacol.
354:
431-436,
1996[Medline].
This article has been cited by other articles:
![]() |